Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study
Sherif F. Nagueh
The Methodist-DeBakey Heart Center, The Methodist Hospital
Search for more papers by this authorRaffaella Lombardi
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Search for more papers by this authorYanli Tan
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Search for more papers by this authorJianwen Wang
The Methodist-DeBakey Heart Center, The Methodist Hospital
Search for more papers by this authorJames T. Willerson
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX, USA
Search for more papers by this authorAli J. Marian
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX, USA
Search for more papers by this authorSherif F. Nagueh
The Methodist-DeBakey Heart Center, The Methodist Hospital
Search for more papers by this authorRaffaella Lombardi
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Search for more papers by this authorYanli Tan
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Search for more papers by this authorJianwen Wang
The Methodist-DeBakey Heart Center, The Methodist Hospital
Search for more papers by this authorJames T. Willerson
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX, USA
Search for more papers by this authorAli J. Marian
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX, USA
Search for more papers by this authorSee Editorial on page 965.
Abstract
Eur J Clin Invest 2010; 40 (11): 976–983
Background Hypertrophic cardiomyopathy (HCM) is a genetic paradigm of cardiac hypertrophy. Cardiac hypertrophy is a major determinant of risk of sudden death and morbidity in HCM. Treatment with statins reverses hypertrophy in animal models of HCM. Thus, statins may afford therapeutic benefits in HCM.
Methods We performed a feasibility study with atorvastatin to gather the pre-requisite data for designing randomized efficacy studies.
Results We screened 32 patients with HCM in 18 months. Twenty-one patients met the study criteria and consented to participate. The demographics and echocardiographic phenotype of those who did and those who did not participate were not significantly different. We treated the participants with escalating doses of atorvastatin (20, 40 and 80 mg day−1) for 2 years. We performed ECG and echocardiography and measured plasma lipids, liver enzymes, creatine kinase and B-type natriuretic peptide levels before and after 3, 6, 12 and 24 months of therapy. Fifteen, 12 and 11 patients completed 6, 12 and 24 months of therapy respectively. Six patients discontinued atorvastatin because of perceived lack of benefit. We stopped atorvastatin in 4 patients because of modest elevations in liver enzymes, creatine kinase or back pain. The characteristics of those who did or did not complete the study were not significantly different. The mean plasma low-density lipoprotein-cholesterol level was reduced by 55%. However, echocardiographic indices of cardiac hypertrophy and function remained unchanged.
Conclusions The findings illustrated the challenges that will be encountered in designing efficacy studies to test the potential beneficial effects of atorvastatin in human HCM.
References
- 1 Tam SK, Gu W, Mahdavi V, Nadal-Ginard B. Cardiac myocyte terminal differentiation. Potential for cardiac regeneration. Ann N Y Acad Sci 1995; 752: 72–9.
- 2 Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308–20.
- 3 Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 2009; 119: 1085–92.
- 4 Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276: 199–204.
- 5 Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–6.
- 6 Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317: 168–75.
- 7 Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778–85.
- 8 Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32: 1454–9.
- 9 Elliott PM, Gimeno B Jr, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420–4.
- 10 Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315–21.
- 11 Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879–84.
- 12 Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, Lombardi R et al. Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2007; 101: 1049–57.
- 13 Matsumura Y, Elliott PM, Virdee MS, Sorajja P, Doi Y, McKenna WJ. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 2002; 87: 247–51.
- 14 McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004; 109: 1756–62.
- 15 Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001; 104: 128–30.
- 16 Nagueh SF, Kopelen HA, Lim DS, Zoghbi WA, Quinones MA, Roberts R et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000; 102: 1346–50.
- 17 Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH III, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99: 254–61.
- 18 Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002; 105: 2992–7.
- 19 Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58–60.
- 20 Lutucuta S, Tsybouleva N, Ishiyama M, Defreitas G, Wei L, Carabello B et al. Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. J Am Coll Cardiol 2004; 44: 2221–30.
- 21 Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317–24.
- 22 Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005; 97: 285–92.
- 23 Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004; 109: 1284–91.
- 24 Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006; 47: 827–34.
- 25 Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 2009; 119: 1398–407.
- 26 Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003; 108: 395–8.
- 27 Lechin M, Quinones MA, Omran A, Hill R, Yu QT, Rakowski H et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995; 92: 1808–12.
- 28 Romhilt DW, Estes EH Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968; 75: 752–8.
- 29 Bauersachs J, Stork S, Kung M, Waller C, Fidler F, Hoyer C et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007; 37: 852–9.
- 30 Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010; 40: 360–9.
- 31 Marian AJ. Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009; 2: 483–92.
- 32 Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789–91.
- 33 Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002; 109: 1013–20.
- 34 Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M et al. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail 2006; 8: 115–21.
- 35 Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005; 96: 1563–7.
- 36 Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J 2007; 48: 715–24.
- 37 Buyse G, Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003; 60: 1679–81.
- 38 Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6–20.
- 39 Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci 2006; 103: 4628–33.
- 40 Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241–8.
